1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468; MD Anderson-Metastatic Breast-468 |
| Species | Human |
| Cat.No | ABC-TC0657 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
MDA-MB-468 is a human epithelial tumor cell line derived from pleural effusion of a 51-year-old Black female patient with metastatic adenocarcinoma of the breast, classified as triple-negative breast cancer (TNBC). The cell line exhibits characteristics of basal-like TNBC and has an epithelial-like morphology. The cells are small, adherent, and can present multinucleated characteristics as they approach confluence, with debris becoming noticeable. The karyotype is complex, with chromosomal aberrations commonly seen in TNBC. They highly express glucose-6-phosphate dehydrogenase (G6PD). The cell line is tumorigenic in immunodeficient mice, and while metastatic behavior is likely, it is not fully characterized. There are no specific viral properties associated with this cell line, and it serves as a model for studying triple-negative breast cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
MDA-MB-468 is a key model for investigating the gene expression of basal-like TNBC and identifying the signal activators and transducers in signaling pathways that regulate or suppress cell growth and survival. Unlike ER-positive and HER2-amplified cancers, TNBC exhibits stronger resistance to hormone and HER2-targeted therapies, primarily due to the absence of frequent oncogenic driver mutations. Therefore, MDA-MB-468 is crucial in breast cancer research. For instance, the application of MDA-MB-468 in TNBC xenograft models has confirmed the inhibitory effect of IMMU-132, an antibody-drug conjugate targeting Trop-2, on tumor growth.
